GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Imricor Medical Systems Inc (ASX:IMR) » Definitions » Debt-to-EBITDA
中文

Imricor Medical Systems (ASX:IMR) Debt-to-EBITDA : -0.40 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Imricor Medical Systems Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Imricor Medical Systems's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$1.00 Mil. Imricor Medical Systems's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$14.57 Mil. Imricor Medical Systems's annualized EBITDA for the quarter that ended in Dec. 2023 was A$-38.95 Mil. Imricor Medical Systems's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.40.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Imricor Medical Systems's Debt-to-EBITDA or its related term are showing as below:

ASX:IMR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.48   Med: -0.12   Max: -0.04
Current: -0.48

During the past 6 years, the highest Debt-to-EBITDA Ratio of Imricor Medical Systems was -0.04. The lowest was -0.48. And the median was -0.12.

ASX:IMR's Debt-to-EBITDA is ranked worse than
100% of 430 companies
in the Medical Devices & Instruments industry
Industry Median: 1.225 vs ASX:IMR: -0.48

Imricor Medical Systems Debt-to-EBITDA Historical Data

The historical data trend for Imricor Medical Systems's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imricor Medical Systems Debt-to-EBITDA Chart

Imricor Medical Systems Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial -0.04 -0.12 -0.09 -0.27 -0.48

Imricor Medical Systems Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only -0.09 -0.09 -0.31 -0.35 -0.40

Competitive Comparison of Imricor Medical Systems's Debt-to-EBITDA

For the Medical Devices subindustry, Imricor Medical Systems's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imricor Medical Systems's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Imricor Medical Systems's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Imricor Medical Systems's Debt-to-EBITDA falls into.



Imricor Medical Systems Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Imricor Medical Systems's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.998 + 14.571) / -32.674
=-0.48

Imricor Medical Systems's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.998 + 14.571) / -38.952
=-0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Imricor Medical Systems  (ASX:IMR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Imricor Medical Systems Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Imricor Medical Systems's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Imricor Medical Systems (ASX:IMR) Business Description

Traded in Other Exchanges
N/A
Address
400 Gateway Boulevard, Burnsville, MN, USA, 55337
Imricor Medical Systems Inc is a medical device company engaged in addressing issues with traditional x-ray-guided ablation procedures through the development of MRI-guided technology. The products of the company include Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter and Vision-MR Dispersive Electrode.

Imricor Medical Systems (ASX:IMR) Headlines

No Headlines